Drugs / AB-1015
AB-1015
also known as
Integrated Circuit T (ICT) cells
Cell therapy targets ALPG, MSLN via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05617755 | Nov 2022 → Sep 2024 overdue | fallopian tube neoplasm, glandular cell neoplasm, malignant epithelial tumor of ovary, peritoneal neoplasm | Arsenal Biosciences, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-1015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05617755 ↗ |
| Known as | Integrated Circuit T (ICT) cells | “The purpose of this study is to test the safety of using a new treatment called Integrated Circuit T (ICT) cells (AB-1015 cells) in patients with ovarian cancer.” NCT05617755 ↗ |
| Action | Deplete | “These logic-gated T cells may help the body's immune system identify and kill cancer cells” NCT05617755 ↗ |
| Modality | Cell therapy | “autologous T cell therapy” NCT05617755 ↗ |
| Route | Intravenous | “The AB-1015 cells are given intravenously” NCT05617755 ↗ |
| Target | ALPG | “The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ...” NCT05617755 ↗ |
| Target | MSLN | “The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ...” NCT05617755 ↗ |